GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (NAS:PHXM) » Definitions » 6-1 Month Momentum %

PHAXIAM Therapeutics (PHAXIAM Therapeutics) 6-1 Month Momentum % : -11.33% (As of May. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PHAXIAM Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-06), PHAXIAM Therapeutics's 6-1 Month Momentum % is -11.33%.

The industry rank for PHAXIAM Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

PHXM's 6-1 Month Momentum % is ranked worse than
80.88% of 1517 companies
in the Biotechnology industry
Industry Median: 0.17 vs PHXM: -11.33

Competitive Comparison of PHAXIAM Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, PHAXIAM Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PHAXIAM Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's 6-1 Month Momentum % falls into.



PHAXIAM Therapeutics  (NAS:PHXM) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PHAXIAM Therapeutics  (NAS:PHXM) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


PHAXIAM Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


PHAXIAM Therapeutics (PHAXIAM Therapeutics) Business Description

Traded in Other Exchanges
Address
60 Avenue Rockefeller, Lyon, FRA, 69008
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.